GlassScriptPhysician profile
Ronald L Cox
NPI 1962404699
$12,115.03
in general payments reported to CMS, 2019-2025
34 companies · $2,181 in 2025
The $2,181 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $939 · 2021: $1,611 · 2022: $1,923 · 2023: $2,274 · 2024: $2,382 · 2025: $2,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,750 · Consulting Fee: $53.05 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,750.35 |
| Consulting Fee | $53.05 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,867.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,503.91 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,128.87 | 2019-2025 | Dupixent |
| Optinose US, INC. | $549.91 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $539.77 | 2020-2024 | Cuvitru, Takhzyro |
| Novartis Pharmaceuticals Corporation | $531.66 | 2019-2025 | |
| Genzyme Corporation | $499.09 | 2019-2025 | |
| Octapharma USA, INC. | $384.50 | 2021-2025 | Octagam Immune Globulin (Human), Cutaquig |
| Amgen INC. | $369.85 | 2019-2025 | Tezspire |
| Csl Behring | $362.81 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Genentech USA, INC. | $344.37 | 2020-2025 | Xolair |
| Biocryst US Sales Co., LLC | $243.12 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $241.09 | 2021-2025 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $237.16 | 2025 | Neffy |
| Alafair Biosciences, INC. | $213.53 | 2024 | Versawrap |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $191.13 | 2019-2024 | Auvi-Q |
| Depuy Synthes Sales INC. | $148.45 | 2024 | Va-Lcp |
| Mylan Specialty L.P. | $116.13 | 2020-2022 | |
| Pfizer INC. | $91.78 | 2020-2025 | |
| Greer Laboratories, INC. | $81.97 | 2019-2025 | Oralair |
| Grifols USA, LLC | $75.52 | 2022-2025 | Xembify |
| Hikma Pharmaceuticals USA | $66.60 | 2023-2024 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $65.37 | 2022 | |
| Adma Biomanufacturing LLC | $53.05 | 2024 | |
| Azurity Pharmaceuticals, INC. | $38.51 | 2025 | Alvesco |
| Shire North American Group INC | $36.33 | 2019 | |
| Organon LLC | $23.85 | 2025 | |
| Alk-Abello, INC | $23.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.08 | 2021 | |
| Convatec INC. | $16.51 | 2023 | |
| Blueprint Medicines Corporation | $15.91 | 2024 | Ayvakit |
| Merck Sharp & Dohme LLC | $15.32 | 2021 | |
| Novo Nordisk INC | $12.56 | 2020 | |
| Cycle Pharmaceuticals INC | $6.44 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.